Vericel Reaffirms MACI Guidance for 2022

Vericel reported 1Q22 orthopedic sales of $26 million, +9.2% vs. 1Q21.

According to the company, MACI vastly outperformed the overall cartilage repair market. Additionally, the Vericel active surgeon population grew in the double digits during the first quarter while March brought the second-highest biopsy volume since launch.

The company...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us